|
 |
RapamuneThis page contains recent news articles, when available, and an overview of Rapamune but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Rapamune (when available) Sirolimus, a macrocyclic lactone produced by Streptomyces hygroscopicus, is an immunosuppressive agent indicated for the prophylaxis of organ rejection in patients receiving renal transplants. It is recommended that Sirolimus be used in a regimen with cyclosporine and corticosteroids. For the treatmnet of post operative pain Mechanism Of Action: Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, Sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The Sirolimus:FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle. News Articles on Sirolimus Getting a Handle on Posttransplant Recurrence of HCC - Dec 17, 2009 Two other promising agents that are unproven include the oral agent sorafenib (Nexavar), and the immunosuppressant sirolimus (Rapamune). ... Cancer Network 美国FDA更新部分抗排异è?¯è¯´æ˜Žä¹¦ è¦ç¤ºå¢žåŠ 感染风险 - Jan 3, 2010 ...需è¦?修改说明书的è?¯ç‰©æœ‰ï¼šRapamune（西罗莫å?¸ï¼‰ã€?Sandimmune（山地明，通用å??：环å¢æ¯’ç´ A）和环å¢æ¯’ç´ A仿制è?¯ã€?Neoral（环å¢æ¯’ç´ Aè¡?生物）和Neoral仿制 ... 中国武汉 Rapamuneâ„¢ May Improve Responses to Gleevec® in Patients with Chordoma - Nov 4, 2009 Researchers from Italy have reported that the addition of Rapamune® (sirolimus, rapamycin) to Gleevec® (imatinib) may improve disease control in patients ... Cancer Consultants … New Dosing Recommendations For RAPAMUNE In High Immunologic … - Feb 3, 2007 Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that the US Food and Drug Administration (FDA) has approved new dosing ... Medical News Today - Medical News Today (press release) Kidney Transplant Patients Who Took Rapamune(R) Achieved Superior … - May 23, 2005 SEATTLE, May 23 /PRNewswire-FirstCall/ -- Data from a large comparative study presented today at the American Transplant Congress showed that kidney ... RedOrbit US FDA says Roche cancels heart transplant study - Feb 22, 2007 N under the brand name Rapamune. Immunosuppressant drugs aim to prevent organ rejection in people who have undergone transplant surgery. ... Reuters … New Dosing Recommendations for RAPAMUNE in High Immunologic … - Feb 2, 2007 MADISON, NJ, Feb. 2 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , today announced that the US Food and Drug Administration (FDA) ... Free with registration - PR Newswire - AccessMyLibrary.com Health Canada Endorsed Important Safety Information on Rapamune ( … - Aug 25, 2006 In Canada, Rapamune® is authorized for the prevention of rejection only in patients who ... Such patients should continue to use Rapamune® as prescribed. ... DG News Terminally Ill Kids Get `Chance' of Cancer Cure From Wyeth Drug - Jun 26, 2008 After the researchers found that Rapamune, also known as rapamycin, showed activity against the cells, Canadian regulators said the drug could be tested in ... Bloomberg Medical News: General Nephrology - Mar 30, 2005 Consider using Rapamune (sirolimus) for immunosuppression in kidney transplant patients who develop Kaposi's sarcoma, as an alternative the standard ... MedPage Today … dosing recommendations for Wyeth's Rapamune in high immunologic … - Mar 1, 2007 The company says Rapamune is the first and only kidney transplant drug with dosing recommendations specifically for the treatment of high immunologic risk ... Pay-Per-View - Transplant News - HighBeam Research Is Wyeth's Torisel Better Than Wyeth's Rapamune? - Jun 6, 2007 Torisel is a prodrug of Rapamune, Wyeth's marketed immunosuppressant product. It is possible that cost concerns could lead to use of Rapamune as a "poor ... Gerson Lehrman Group Study Suggests Drug-Eluting Stent Type And - May 16, 2006 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune®. ... Angioplasty.Org Wyeth's Rapamune shown to reduce cancer risk in transplant recipients. - Nov 21, 2005 The Rapamune maintenance regimen trial, the largest randomized cyclosporine-withdrawal assessment undertaken to date, enrolled 430 patients from Europe, ... $4.95 - Pharma Marketletter - ECNext Drug Takes Aim at Kidney Transplant Rejection - Nov 24, 2006 The study involved about 450 high-risk patients who were randomly assigned to receive sirolimus (Rapamune) and the standard anti-rejection drug tacrolimus ... Ivanhoe Broadcast News … Transplant Patients Receiving Rapamune Without Cyclosporine Sho - Oct 19, 2005 Five Year Study Shows That Renal Transplant Patients Receiving Rapamune Without Cyclosporine Show Reduced Incidence of Non-Skin Cancer. from PR Newswire ... Pay-Per-View - PR Newswire Europe - HighBeam Research New Rapamune dosing guide OKed by FDA. - Feb 12, 2007 New Jersey, USA-based Wyeth Pharmaceuticals says that the Food and Drug Administration has cleared new dosing recommendations for its immunosuppressant ... Free with registration - Pharma Marketletter - AccessMyLibrary.com … : Kidney Transplant Patients Who Took Rapamune(R) Achieved Superior... - May 23, 2005 Kidney Transplant Patients Who Took Rapamune(R) Achieved Superior Graft Survival at 4 Years After Early Cyclosporine Withdrawal. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Rapamune.(NEW DOSING)(Food and Drug Administration)(Brief article) - Mar 5, 2007 The FDA has approved new dosing recommendations for Rapamune (sirolimus), from Wyeth Pharmaceuticals, Madison, NJ, (973) 660-5000. ... Free with registration - Drug Topics - AccessMyLibrary.com … New Dosing Recommendations for RAPAMUNE in High Immunologic … - Feb 2, 2007 FDA Approves New Dosing Recommendations for RAPAMUNE in High Immunologic Risk Renal Transplant Patients. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research … device for Wyeth's Rapamune.(Abbott Laboratories manufacturing … - May 2, 2005 Drug Administration for an automated test for monitoring the therapeutic levels of Wyeth's anti-rejection drug, Rapamune (sirolimus), in whole blood. ... $4.95 - Pharma Marketletter - ECNext Long Term Sirolimus Data Brings Hope for Kidney Transplant Patients. - Jan 31, 2005 4,5) Sirolimus (rapamycin, Rapamune(R)) is an immunosuppressive that is not nephrotoxic. The results clearly highlight sirolimus as a major advance in ... $4.95 - PR Newswire - ECNext LifeCycle Pharma Announces New Product Candidate; Initiates Phase I … - Nov 29, 2007 Sirolimus is today marketed by Wyeth under the brand name Rapamune[R]. Rapamune is sold as an oral solution and tablet and coats the CYPHER coronary stent ... Free with registration - Business Wire - AccessMyLibrary.com CsA withdrawal reduces cancer risk - Oct 20, 2005 ...than patients who stay on a combination of cyclosporine plus sirolimus, five-year data from the Rapamune Maintenance Regimen (RMR) trial suggest [ 1 ]. ... Medscape Rapamune. - Mar 5, 2007 The FDA has approved new dosing recommendations for Rapamune (sirolimus), from Wyeth Pharmaceuticals, Madison, N.J., (973) 660-5000. ... $9.94 - Drug Topics - Alacra Store Rapamune. - Mar 1, 2007 FDA approved new dosing recommendations for sirolimus (Rapamune, Wyeth) for the treatment of renal transplant recipients at high immunologic risk. ... $9.94 - Formulary - Alacra Store Early steroid withdrawal after renal transplantation.(Practice Issues... - Jan 1, 2006 Dose reduction or temporary cessation of Rapamune[R] or Cellcept[R] is ... Although steroids also contribute to increased serum lipids, Rapamune[R] can ... Free with registration - Nephrology Nursing Journal - AccessMyLibrary.com Empresas.-Combinar 'Rapamune' (Wyeth) y micofenolato mejora la … - Jul 16, 2008 La asociación de micofenolato mofetilo y sirolimus, comercializado como 'Rapamune' por los laboratorios Wyeth, como terapia inmunosupresora de mantenimiento ... ecodiario Infliximab Injection Side Effects from Consumer Reports Health. - Jan 4, 2007 Sandimmune), oral corticosteroids; 6-mercaptopurine (Purinethol); methotrexate (Rheumatrex), sirolimus (Rapamune), and tacrolimus (Prograf). ... consumerreports.org La Rapamune, ou comment accepter son greffon - Jun 6, 2008 Des chercheurs de l'University of California de San Diego, dirigés par Robert Steiner, Professeur en Médecine et Directeur du "Transplant Nephrology", ... bulletins-electroniques.com Press Release: Abbott and Axis-Shield Announce US 510(K) Clearance … - Apr 19, 2005 Wyeth's anti-rejection drug, Rapamune (sirolimus), in whole blood. The assay utilizes Abbott's IMx System, an automated ... in patients. ... Pay-Per-View - PR Newswire - HighBeam Research Abbott and Axis-Shield Announce US 510(K) Clearance of an Automated … - Apr 19, 2005 RAPAMUNE is indicated for the prophylaxis of organ rejection in patients aged 13 ... It is recommended that RAPAMUNE be used initially in a regimen with ... $4.95 - PR Newswire - ECNext Rapamune tablet - Apr 28, 2005 ...* Dit geneesmiddel is alleen aan u voorgeschreven. Geef het dus niet door aan iemand anders. Het kan schadelijk voor hen zijn, zelfs als ze dezelfde ... Consumed Enticing cells to 'eat' Huntington's - May 8, 2007 Although Rapamune is precribed over long periods to prevent rejection in transplant patients, there are side-effects associated with its use, including an ... DrugResearcher.com Immune rejection drug shrinks rare tumors - Jan 9, 2008 N drug Rapamune dramatically reduces rare growths known as angiomyolipomas ... In four of the patients, Rapamune had to be stopped because of side effects, ... Reuters Immune rejection drug shrinks rare tumors - Jan 10, 2008 BOSTON (Reuters) - The Wyeth drug Rapamune dramatically reduces rare growths ... In four of the patients, Rapamune had to be stopped because of side effects ... Reuters India Ð’ СШÐ? разработаны новые рекомендации по применению препарата - Feb 7, 2007 FDA разработало новые рекомендации по режиму дозированиÑ? препарата RAPAMUNE® (Sirolimus) компании Wyeth Pharmaceuticals. Ðто ЛС предназначено длÑ? применениÑ? ... ФармацевтичеÑ?кий веÑ?тник The prospect of quick riches has biotechs targeting the rarest of... - Oct 31, 2005 Rapamune was discovered in 1975, but only 20 years later did scientists figure out how it really worked:by hitting a cell receptor called mTOR, ... Pay-Per-View - Forbes - Factiva, from Dow Jones Study finds low-dose Pharma drug best after transplant - Dec 19, 2007 It was highest -- 37 percent -- for low-dose Rapamune, known generically as sirolimus. After one year, the survival rate for the transplanted kidneys was ... Reuters Press Release: International Cyclosporine-Withdrawal Trial Shows … - Nov 13, 2005 This analysis was part of the largest randomized cyclosporine-withdrawal study undertaken to date, the Rapamune Maintenance Regimen (RMR) Study. ... Pay-Per-View - PR Newswire Europe - HighBeam Research Proteinuria following conversion from azathioprine to sirolimus in... - Aug 16, 2006 In a randomized, prospective, multicenter study called RESCUE (Recurrent cutanEous Squamous cell Carcinoma Under RapamunE) the efficacy and safety is ... Nature.com Wyeth Reports Earnings Results for the 2005 Third Quarter and First... - Oct 21, 2005 RAPAMUNE(R), indicated for the prophylaxis of organ rejection in patients ... Prescription volume for Rapamune is currently growing at more than three times ... $4.95 - PR Newswire - ECNext Philadelphia Inquirer, The : Clearing the Record - Nov 6, 2008 Rapamune is provided to Hawk through RapAssist, the Wyeth Pharmaceutical Assistance Foundation's specialized program for individuals who cannot afford the ... $2.95 - Philadelphia Inquirer - NewsBank Philadelphia Inquirer, The (PA) - Nov 6, 2008 Rapamune is provided to Hawk through RapAssist, the Wyeth Pharmaceutical Assistance Foundation's specialized program for individuals who cannot afford the ... $2.95 - Philadelphia Inquirer - NewsBank International Cyclosporine-Withdrawal Trial Shows Reduced Incidence... - Nov 13, 2005 This analysis was part of the largest randomized cyclosporine-withdrawal study undertaken to date, the Rapamune Maintenance Regimen (RMR) Study. ... Free with registration - PR Newswire - AccessMyLibrary.com New Randomized Clinical Trial Results Show the Cypher(R) Sirolimus- … - Oct 23, 2006 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... Free with registration - PR Newswire - AccessMyLibrary.com SMART-Studie: Sirolimus 2-3 Wochen nach Nierentransplantation … - Oct 8, 2008 Sirolimus (Rapamune®) sollte initial in Kombination mit Ciclosporin Mikroemulsion und ... Rapamune® kann zusammen mit Kortikosteroiden im Rahmen einer ... journalmed.de The place of sirolimus in kidney transplantation: Can we reduce … - Jul 26, 2006 Sehgal S. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action ... MacDonald AS, for the Rapamune Study Group. A worldwide, phase III, randomized, ... Nature.com Press Release: Competitive Technologies Licenses Homocysteine Assay … - Apr 28, 2005 Abbott's manufacturing partner Axis-Shield plc, based in Dundee, Scotland ... available at www.rapamune.com . Axis-Shield is a global manufacturer of in ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: International Cyclosporine-Withdrawal Trial Shows … - Nov 13, 2005 This analysis was part of the largest randomized cyclosporine-withdrawal study undertaken to date, the Rapamune Maintenance Regimen (RMR) Study. ... Pay-Per-View - PR Newswire - HighBeam Research Cordis Corporation Announces Plans to Build State-of-the-Art … - Jul 25, 2006 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... Free with registration - PR Newswire - AccessMyLibrary.com Mission Improbable - Oct 21, 2005 Rapamune was discovered in 1975, but only 20 years later did scientists figure out how it really worked:by hitting a cell receptor called mTOR, ... RedOrbit The REALITY Trial and Accompanying Editorial Appear in Prestigious … - Feb 21, 2006 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... Free with registration - PR Newswire - AccessMyLibrary.com Patient Enrollment Complete for Pivotal Trial of the NEVO(TM)... - Oct 27, 2008 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... Genetic Engineering News - Genetic Engineering News (press release) Internationale Studie zum Absetzen von Cyclosporin zeigt gesenkte … - Nov 13, 2005 Zum Fünfjahreszeitpunkt hatten 18 Patienten, die Rapamune plus Cyclosporin eingenommen hatten, einen Nicht-Haut-Krebs entwickelt im Vergleich zu acht ... presseportal.ch DATA SUGGEST DRUG-ELUTING STENTS DIFFER IN RATE OF BLOOD … - Mar 7, 2005 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com Two-Year Data Suggest Different Rates Of Blood Clots And Heart... - Sep 6, 2006 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... Medical News Today - Medical News Today (press release) Transplant Medicine; Long term data on implant rejection is hopeful... - Feb 28, 2005 Sirolimus (rapamycin, Rapamune) is an immunosuppressive that is not nephrotoxic. The results clearly highlight sirolimus as a major advance in ... Pay-Per-View - Gastroenterology Week - Factiva, from Dow Jones TCT2008 Concludes with Presentation of Positive Data for the CYPHER( … - Oct 30, 2008 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... Genetic Engineering News - Genetic Engineering News (press release) Transplant Medicine; Long term data on implant rejection is hopeful... - Mar 3, 2005 Sirolimus (rapamycin, Rapamune) is an immunosuppressive that is not nephrotoxic. The results clearly highlight sirolimus as a major advance in ... Pay-Per-View - Blood Weekly - Factiva, from Dow Jones Transplant Medicine; Long term data on implant rejection is hopeful... - Mar 5, 2005 Sirolimus (rapamycin, Rapamune) is an immunosuppressive that is not nephrotoxic. The results clearly highlight sirolimus as a major advance in ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Article: New dosing.(RXs)(Brief article) - Chain Drug Review |... - Apr 23, 2007 U.S. Food and Drug Administration (FDA) has approved new dosing recommendations for its immunosuppressant drug RAPAMUNE ... corticosteroids for the first ... Pay-Per-View - Chain Drug Review - HighBeam Research Federal Register 2005 - 70 FR 43440 Summaries of Medical and Clinical - Jul 27, 2005 RAPAMUNE (sirolimus), and ZOFRAN (ondansetron). The summaries are being made available consistent with section 9 of the BPCA (Public Law 107-109). ... Pay-Per-View - Federal Register 2005 - Loislaw Nanotechnology raises hopes for better drugs, diagnostics. - Apr 27, 2006 Other available nano drugs include Rapamune, developed by Wyeth Pharmaceuticals and approved in 1999 to prevent organ rejection in kidney transplant ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com People in the News - Aug 13, 2007 Orlando was most recently at Wyeth as the executive director of Rapamune global ... Rapamune is an immunosuppressant drug for the prevention of transplant ... $2.95 - Philadelphia Inquirer - NewsBank Newly Published Data Suggest Better Outcomes With The CYPHER® … - Mar 12, 2006 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune®. ... Angioplasty.Org TRANSPLANTS' CANCER THREAT ; EXPERTS SAY PATIENTS … - Dec 4, 2005 ...patients who took cyclosporine, tacrolimus or similar drugs versus those treated with newer drugs called mTOR inhibitors, such as Rapamune or Rapamycin. ... Pay-Per-View - Richmond Times - Dispatch - ProQuest Archiver CORDIS CORP TO DEVELOP GLOBAL CARDIAC, VASCULAR … - Apr 5, 2006 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... Free with registration - AsiaPulse News - AccessMyLibrary.com Press Release: Making Tailored Medical Treatment a Reality: New... - Aug 18, 2005 Article: FDA Approves New Indication for RAPAMUNE(R); - New Drug ... PR Newswire; April 11, 2003 ; 700+ words ...Wyeth Pharmaceuticals, the pharmaceutical ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Long Term Sirolimus Data Brings Hope for Kidney … - Jan 31, 2005 Article: Kidney Transplant Patients Who Took Rapamune(R) ... PR Newswire; May 23, 2005 ; 700+ words ... ... Transplant Congress showed that kidney ... Pay-Per-View - PR Newswire - HighBeam Research CYPHER STENT OVERLAP BETTER THAN BMS OVERLAP. - Sep 1, 2006 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... Free with registration - Biotech Equipment Update - AccessMyLibrary.com Media Release: Cordis Corporation. - Oct 21, 2005 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com Elan Announces the Johnson & Johnson Pharmaceutical Research … - Oct 29, 2007 Rapamune[R] is a registered trademark owned by Wyeth Pharmaceuticals. Emend[R] is a registered trademark owned by Merck & Co., Inc. Free with registration - Business Wire - AccessMyLibrary.com New study results suggest better outcomes with the CYPHER® Stent than... - Oct 17, 2005 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(r). ... eurekalert.org CYPHER® Sirolimus-Eluting Coronary Stent to Be Featured in Late- … - Feb 28, 2005 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune®. ... i-newswire.com Data Suggest Different Outcomes Between The CYPHER(R) Sirolimus- … - Oct 4, 2006 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... Free with registration - PR Newswire - AccessMyLibrary.com REALITY TRIAL DATA RELEASED. - Mar 9, 2005 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com LOS TRASPLANTADOS DE RIÑÓN TRATADOS CON SIROLIMUS … - May 24, 2005 Este estudio reporta una mayor supervivencia del trasplante renal en aquellos pacientes a los que se les mantuvo con una terapia de RAPAMUNE® (sirolimus) y ... acceso.com NEJM, JAMA ARTICLES UNDERSCORE CLINICAL BENEFITS OF … - Aug 17, 2005 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... $4.95 - AsiaPulse News - ECNext New Long-Term Data Suggest Clinical Differences in Safety and... - Oct 22, 2007 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune[R]. ... Free with registration - Business Wire - AccessMyLibrary.com CYPHER(R) Sirolimus-eluting Coronary Stent Had Similar Results to … - Mar 26, 2007 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... Free with registration - PR Newswire - AccessMyLibrary.com GROWING BODY OF EVIDENCE EXAMINES CYPHER CORONARY … - Feb 24, 2005 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... Free with registration - AsiaPulse News - AccessMyLibrary.com Roche extends NanoCrystal license - Jan 10, 2005 Rapamune was previously available only as an oral solution in bottles or sachets. The oral solution requires refrigeration storage, and must be mixed with ... In-PharmaTechnologist.com CYPHER® Sirolimus-Eluting Coronary Stent Receives FDA Approval for … - Apr 20, 2005 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune®. ... Angioplasty.Org Cordis' Manufacturing Facility Recognized With Shingo Prize for … - Feb 8, 2007 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... Free with registration - PR Newswire - AccessMyLibrary.com Cordis Corporation to Emphasize Commitment to Interventional … - Mar 20, 2007 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... Free with registration - PR Newswire - AccessMyLibrary.com Study Suggests CYPHER(R) Sirolimus-Eluting Coronary Stent More Cost- … - Jul 27, 2006 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... Free with registration - PR Newswire - AccessMyLibrary.com Cordis Corporation's Third-Generation Coronary Stent Approved For Use... - Jun 22, 2006 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune®. ... Angioplasty.Org CYPHER STENT OUTPERFORMS TAXUS STENT IN LONG CORONARY … - Dec 1, 2006 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... Free with registration - Biotech Equipment Update - AccessMyLibrary.com Arts II Clinical Study Shows Promising Results for the Cypher(R) … - Mar 6, 2005 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... Free with registration - PR Newswire Europe - AccessMyLibrary.com Better Patient Outcomes with CYPHER(R) Sirolimus-Eluting Coronary … - Jun 4, 2007 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune . ... Free with registration - M2 Presswire - AccessMyLibrary.com CYPHER® Sirolimus-Eluting Coronary Stent Receives FDA Approval for … - Apr 24, 2005 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune®. ... i-newswire.com CYPHER(R) Sirolimus-Eluting Coronary Stent Outperforms Taxus Stent in... - Feb 2, 2006 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... Free with registration - PR Newswire - AccessMyLibrary.com Preliminary Long-Term Clinical Data Show Promising Results for the … - Nov 15, 2006 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... Free with registration - PR Newswire - AccessMyLibrary.com Cordis Corporation Submits Pre-Market Approval Submission For … - May 13, 2006 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... Medical News Today - Medical News Today (press release) Cordis Corporation Announces Clinical Studies And Events At TCT 2007 - Oct 21, 2007 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune®. ... Medical News Today - Medical News Today (press release) CORDIS PLANS MANUFACTURING FACILITY IN IRELAND. - Sep 1, 2006 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... Entrepreneur Positive CYPHER(R) Stent Data on Complex Cardiac Patients Presented … - Sep 6, 2005 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). ... RedOrbit Sirolimus Reduces the Risk of Cancer in Kidney Transplant Patients - Feb 9, 2006 In this analysis of the Rapamune Maintenance Study, 430 kidney transplant patients were randomly assigned to remain on sirolimus (SRL), cyclosporine (CsA) ... DG News CYPHER® Sirolimus-Eluting Coronary Stent Demonstrates Sustained … - Sep 10, 2007 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune®. ... Medical News Today - Medical News Today (press release) CYPHER® Sirolimus-Eluting Coronary Stent Demonstrates Sustained … - Apr 2, 2007 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune®. ... Medical News Today - Medical News Today (press release) CYPHER® Sirolimus-Eluting Coronary Stent Had Similar Results To … - May 29, 2007 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune®. ... Medical News Today - Medical News Today (press release) Safety and Efficacy of the Cypher(R) Sirolimus-Eluting Coronary Stent... - Jun 8, 2005 Rapamune is a trademark of Wyeth Pharmaceuticals. Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery ... Medical News Today - Medical News Today (press release) Brand Names/Synonyms: Rapamune is also known by the following brand names and/or synonymsAntibiotic Ay 22989; Rapamune; Rapamycin; Rapamycin / Sirolimus; Rapamycin, ≪ 98% by Tlc; Sirolimus; Sirolimus [Usan:Ban:Inn] Drug Category: Rapamune is categorized under the following by the FDA: Immunosuppressive Agents; Antifungals; Antibiotics; Anti-bacterial Agents; Unclassified Therapeutic Agents (92:00.00); ATC:L04AA10 Dosage Forms: SOLUTION Absorption: Not Available Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: Not Available |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |